Biotech stocks have been dropping in value since early February, likely depressed by some regulatory and drug pricing concerns, but some analysts think the sector will rebound later this year, partly on the back of M&A deals and new product releases.... [+]
David Nierengarten, a biotech and biopharmaceuticals analyst at Wedbush Securities in Los Angeles, toldthat concerns over stalled new drug approvals by the Food and Drug Administration are likely weighing on the biotech sector.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: